U.S. flag

An official website of the United States government

NM_000110.4(DPYD):c.775A>G (p.Lys259Glu) AND not specified

Germline classification:
Benign (3 submissions)
Last evaluated:
Jun 21, 2022
Review status:
2 stars out of maximum of 4 stars
criteria provided, multiple submitters, no conflicts
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV000249889.11

Allele description [Variation Report for NM_000110.4(DPYD):c.775A>G (p.Lys259Glu)]

NM_000110.4(DPYD):c.775A>G (p.Lys259Glu)

Gene:
DPYD:dihydropyrimidine dehydrogenase [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
1p21.3
Genomic location:
Preferred name:
NM_000110.4(DPYD):c.775A>G (p.Lys259Glu)
HGVS:
  • NC_000001.11:g.97679170T>C
  • NG_008807.2:g.246890A>G
  • NM_000110.4:c.775A>GMANE SELECT
  • NP_000101.2:p.Lys259Glu
  • NP_000101.2:p.Lys259Glu
  • LRG_722t1:c.775A>G
  • LRG_722:g.246890A>G
  • LRG_722p1:p.Lys259Glu
  • NC_000001.10:g.98144726T>C
  • NM_000110.3:c.775A>G
Protein change:
K259E
Links:
dbSNP: rs45589337
NCBI 1000 Genomes Browser:
rs45589337
Molecular consequence:
  • NM_000110.4:c.775A>G - missense variant - [Sequence Ontology: SO:0001583]
Observations:
4

Condition(s)

Synonyms:
AllHighlyPenetrant
Identifiers:
MedGen: CN169374

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV000302306PreventionGenetics, part of Exact Sciences
criteria provided, single submitter

(ACMG Guidelines, 2015)
Benigngermlineclinical testing

PubMed (1)
[See all records that cite this PMID]

SCV000700574Eurofins Ntd Llc (ga)
criteria provided, single submitter

(EGL Classification Definitions 2015)
Benign
(Nov 9, 2016)
germlineclinical testing

Citation Link,

SCV000917305Women's Health and Genetics/Laboratory Corporation of America, LabCorp
criteria provided, single submitter

(LabCorp Variant Classification Summary - May 2015)
Benign
(Jun 21, 2022)
germlineclinical testing

PubMed (5)
[See all records that cite these PMIDs]

Citation Link

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineunknown4not providednot providednot providednot providedclinical testing

Citations

PubMed

Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.

Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, Voelkerding K, Rehm HL; ACMG Laboratory Quality Assurance Committee.

Genet Med. 2015 May;17(5):405-24. doi: 10.1038/gim.2015.30. Epub 2015 Mar 5.

PubMed [citation]
PMID:
25741868
PMCID:
PMC4544753

Evaluation of ultra-deep targeted sequencing for personalized breast cancer care.

Harismendy O, Schwab RB, Alakus H, Yost SE, Matsui H, Hasteh F, Wallace AM, Park HL, Madlensky L, Parker B, Carpenter PM, Jepsen K, Anton-Culver H, Frazer KA.

Breast Cancer Res. 2013 Dec 10;15(6):R115. doi: 10.1186/bcr3584.

PubMed [citation]
PMID:
24326041
PMCID:
PMC3978701
See all PubMed Citations (6)

Details of each submission

From PreventionGenetics, part of Exact Sciences, SCV000302306.1

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (1)
#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

From Eurofins Ntd Llc (ga), SCV000700574.3

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not provided4not providednot providedclinical testingnot provided
#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot provided4not providednot providednot provided

From Women's Health and Genetics/Laboratory Corporation of America, LabCorp, SCV000917305.2

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (5)

Description

Variant summary: DPYD c.775A>G (p.Lys259Glu) results in a conservative amino acid change located in the FAD/NAD(P)-binding domain of the encoded protein sequence. Three of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 0.0061 in 251782 control chromosomes in the gnomAD database, including 12 homozygotes. The observed variant frequency is approximately 2.5 fold of the estimated maximal expected allele frequency for a pathogenic variant in DPYD causing Dihydropyrimidine Dehydrogenase Deficiency phenotype (0.0025), strongly suggesting that the variant is benign. c.775A>G has been reported in the literature in individuals affected with 5-FU-related toxicity (example Gross_2003, Schwab_2008, Harismendy_2013, Garcia-Gonzalez_2020). One of these studies described that DPYD enzyme activity measured in the cytosolic fraction of PBMCs from a heterozygous patient was in the normal range (Gross_2003). These reports do not provide unequivocal conclusions about association of the variant with Dihydropyrimidine Dehydrogenase Deficiency. At least one publication reports evaluating the impact of the variant on protein function in an in vitro expression system and found no damaging effect on enzymatic activity (Offer_2014). Five clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. Three laboratories classified the variant as benign, one as likely benign, and one as VUS. Based on the evidence outlined above, the variant was classified as benign.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Apr 20, 2025